Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

Share Price is delayed by 15 minutes
Get Live Data
1.30    0.00 (0.00%)
Bid:
1.25
Ask:
1.35
Spread: 0.10 (8.00%)
Market Cap: £20.87m
GDR Live PriceLast checked at - London Stock Exchange

Intraday Genedrive Share Chart

Distribution agreement

9 Mar 2021 07:00

RNS Number : 5536R
Genedrive PLC
09 March 2021
 

 

 

genedrive plc

("genedrive" or the "Company")

 

Genedrive enters distribution agreement with Mountain Horse Solutions

Distribution of genedrive's Military Assays and Instrument in the United States

 

genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that it has entered into an agreement for the distribution of the Company's military pathogen detection assays in the United States with Mountain Horse Solutions ("Mountain Horse"), a military contracting specialist to U.S. Federal, State, and Local Government customers.

 

genedrive has a unique product with regard to military CBRNE1 requirements. The Genedrive® BioPlex range of products was developed to the U.S. Department of Defense's (U.S. DoD) product specification with the help of U.S. DoD funding. Designed for field portability and rapid determination of biothreats from pathogens, the Genedrive BioPlex system was developed over a period of five years and has been approved to deployment stage.

 

Contracting with the U.S. Government can be challenging and time consuming. The Company believes that establishing new, local representation in the United States with identified contacts in this highly specialised field will help drive broader product uptake. Organisations like Mountain Horse are already contracted with the U.S. Government, which includes existing framework purchasing agreements, providing an opportunity for more rapid order placement and replenishment of products without the need for new contracts to be negotiated.

 

Bill Allen, President of Mountain Horse Solutions, said: "We are delighted to be working with genedrive with these exciting pathogen detection products. The addition of genedrive's assays to our portfolio of CBRNE mission critical products provides a unique offering of combat-ready sampling and detection devices."

 

David Budd, CEO of genedrive plc, said: "The agreement allows the supply of our BioPlex pathogen detection assays through Mountain Horse, a military contracting specialist who has a number of existing framework contracts with target clients such as the U.S. DoD. We believe that they have both the industry sector knowledge and existing commercial arrangements to increase the exposure of our products and gain new customer opportunities within the various branches and departments of the DoD and U.S. Government."

 

1. Chemical Biological Radiological, Nuclear and Explosive

 

For further details please contact:

 

genedrive plc

+44 (0)161 989 0245

David Budd: CEO / Matthew Fowler: CFO

 

 

 

Peel Hunt LLP (Nominated Adviser and Joint Broker)

+44 (0)20 7418 8900

James Steel / Oliver Jackson

 

 

 

finnCap (Joint Broker)

+44 (0)20 7220 0500

Geoff Nash / Kate Bannatyne / Alice Lane

 

 

 

Walbrook PR Ltd (Media & Investor Relations)

+44 (0)20 7933 8780 or genedrive@walbrookpr.com

Paul McManus / Anna Dunphy

+44 (0)7980 541 893 / +44 (0)7876 741 001

 

 

About genedrive plc (http://www.genedriveplc.com) genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets, and has tests in development for tuberculosis (mTB). The Company recently released a high throughput SARS-CoV-2 assay and has in development a Genedrive® Point of Care version of the assay, both based on Genedrive® chemistry.

 

About Mountain Horse Solutions 

Mountain Horse Solutions supplies rapid response customized equipment, systems, and training for infectious disease, security, technology, chemical, biological, radiological, nuclear, and explosive (CBRNE) hazards. We specially design innovative solutions, to meet the individual unique threats, needs, and requirements of the military, and first responders. Our team of professionals from around the globe has extensive experience with commercial, DOD, and U.S. Federal Government customers. Mountain Horse Solutions serves organizations, agencies, and contractors worldwide. To find out more visit: www.mtnhorse.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRBIGDXBXGDGBI
Date   Source Headline
2nd Oct 20256:18 pmRNSHolding(s) in Company
1st Oct 202512:31 pmRNSHolding(s) in Company
1st Oct 202512:30 pmRNSHolding(s) in Company
30th Sep 20259:52 amRNSHolding(s) in Company
29th Sep 20255:03 pmRNSHolding(s) in Company
29th Sep 20253:00 pmRNSPublication of Circular and Notice of GM
29th Sep 20257:00 amRNSResult of Retail Offer
24th Sep 20257:00 amRNSCompletion of Placing
23rd Sep 20255:03 pmRNSProposed Retail Offer
23rd Sep 20254:59 pmRNSProposed Placing to raise a minimum of £3 million
23rd Sep 20259:00 amRNSHolding(s) in Company
23rd Sep 20259:00 amRNSHolding(s) in Company
15th Sep 20254:24 pmRNSResult of General Meeting
10th Sep 20254:15 pmRNSHolding(s) in Company
10th Sep 20254:15 pmRNSHolding(s) in Company
29th Aug 202512:00 pmRNSProposed Share Capital Reorganisation & GM
21st Aug 20257:00 amRNSScotland’s Public Health Minister visit
14th Aug 202510:35 amRNSComment re: Share Price Movement
11th Aug 20257:00 amRNSTrading update
30th May 20257:00 amRNSBlock Listing Returns
30th May 20257:00 amRNSCE-certification
13th May 20257:00 amRNSCYP2C19-ID Kit used to support expansion
2nd May 20251:30 pmRNSCYP2C19 ID Kit CE-IVD certification update
2nd Apr 20257:01 amRNSAdditional grant funding under DEVOTE programme
2nd Apr 20257:00 amRNSReceipt of R&D tax credit
1st Apr 20257:00 amRNSResult of RetailBook Offer
27th Mar 20253:30 pmRNSRetailBook Offer
27th Mar 20253:29 pmRNSHalf-year Report
27th Mar 20253:28 pmRNSEquity Fundraise
17th Mar 202511:04 amRNSScottish Government testing programme investment
14th Mar 20257:00 amRNSCYP2C19-ID Kit adopted for routine clinical use
30th Dec 202411:54 amRNSResult of AGM
27th Dec 20247:00 amRNSGenedrive® CYP2C19-ID Kit performance published
20th Dec 202412:16 pmRNSGrant of Options
20th Dec 202412:12 pmRNSDirector/PDMR Shareholding
5th Dec 20243:00 pmRNSPosting of annual report and notice of AGM
29th Nov 20241:00 pmRNSBlock listing returns
29th Nov 20247:00 amRNSFinal Results
22nd Nov 20247:00 amRNSNotice of Results
21st Nov 202411:06 amRNSNIHR and OLS Funding Package
4th Nov 20241:29 pmRNSScottish Health Technology Group publications
21st Oct 20243:22 pmRNSDirector Declaration
15th Aug 202410:39 amRNSDirector/PDMR Shareholding
12th Aug 20247:00 amRNSFirst UK commercial sales of the CYP2C19-ID Kit
6th Aug 20247:00 amRNSDirectorate Change
31st Jul 20247:00 amRNSNICE recommends CYP2C19-ID Kit in final guidance
15th Jul 20247:00 amRNSBreakthrough Device Designation from the U.S. FDA
27th Jun 20249:28 amRNSShort extension to NICE publication date
25th Jun 20247:00 amRNSHolding(s) in Company
24th Jun 202411:13 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.